BioSuite AI PortfolioSurveillance & ExposureEpiEvidence
EpiEvidence: Explore the story behind the numbers. Investigate epidemiology and outbreak concepts through a research demo. Research demo.
EpiEvidenceInvestigate epidemiology and outbreak concepts through a research demo.Explore the story behind the numbers. · Research demo
PREM KUMARSCIENCE · LEADERSHIP · AI
← Prem Kumar PerumalEpiEvidence DEMO VERSION

OUTBREAK INVESTIGATION · TRANSPARENT ANALYSIS

Explore the pattern.
Challenge the conclusion.

From a participant list to an epidemic curve, exposure comparison and a reviewable report.

Educational prototype by Prem Kumar Perumal. Start with fictional data or de-identified participant records only. No names, addresses or patient identifiers. Calculations do not establish causation or replace an outbreak investigation.

01 / THE INVESTIGATION

Does the association survive?

This cohort workflow needs all relevant participants, including non-cases. A case-only list cannot estimate attack rates or risk ratios for the whole group.

Non-cases stay included. Cases outside the selected definition are excluded—not recoded as healthy. Unknown exposures are excluded from the 2×2 analysis, but included cases remain on the epidemic curve.

Plain CSV, no quotes, up to 1 MB / 5,000 rows. Header: id,onset,status,exposed. Exposure: 1=yes, 0=no, ?=unknown. Status: confirmed, probable, uncertain or noncase.

Inspect participant records

First 50 rows shown; report calculations use every accepted row.

02 / TIME, NOT JUST TOTALS

When did illness begin?

Epidemic curve of included cases by onset date

Counts use symptom-onset dates, not report or laboratory-result dates. Zero-count dates are shown. Bins are exploratory; choose intervals appropriate to the investigation. A shape alone does not identify the source or mode of spread.

03 / CALCULATOR

Inspect a 2×2 table.

Enter counts independently of the imported cohort. Risk calculations apply to cohort data with appropriate denominators; odds ratios can be used for case–control analysis. Case–control sampling does not estimate population attack rates.

04 / DENOMINATORS MATTER

Disease frequency.

For cumulative incidence, count new cases in a defined period among an initially at-risk population. For point prevalence, count existing cases at one point in time. For incidence rate, use total at-risk person-time and document how events are counted. No denominator adjustments, standardisation or confidence intervals are applied here.

05 / REVIEW THE EVIDENCE

Know what the numbers mean.

Risk ratio = [a/(a+b)] ÷ [c/(c+d)]. Odds ratio = ad/bc. Risk difference = exposed risk − unexposed risk. 95% intervals use log-Wald approximations, with 1.96 standard errors. These may perform poorly with sparse data; exact methods are not implemented.

With any zero cell, confidence intervals are withheld. Undefined ratios are shown as “Not estimable”; no automatic continuity correction is added. Associations are unadjusted and do not account for confounding, clustering, selection bias or multiple exposure comparisons.

The case-definition sensitivity panel repeats the same complete-case analysis under three definitions. This is not a missing-data sensitivity analysis. Unknown exposure records require investigation; treating them as unexposed would be misleading.

Beta / Demo. Not a validated surveillance platform. No automatic outbreak alerts, source attribution, geolocation, prediction or public-health notifications. Review data provenance and case definitions before interpreting results.